- Oops!Something went wrong.Please try again later.
Pfizer plans to submit data about its COVID-19 vaccine for children ages 5 to 11 to the Food and Drug Administration "pretty soon," CEO Albert Bourla told ABC's "This Week" on Sunday.
Why it matters: The start of the school year saw a rise in COVID-19 infections among kids, and heightened the focus on when the vaccine will be available for children.
Get market news worthy of your time with Axios Markets. Subscribe for free.
Earlier this week, Pfizer announced that results from its pediatric trial indicate that its vaccine — in a smaller dosage than given to adults — is safe and effective for children ages 5 to 11.
Pfizer CEO @AlbertBourla tells @GStephanopoulos that company is going to submit data to FDA for children’s COVID-19 vaccine “pretty soon.”
“It's a question of days, not weeks.” https://t.co/Ekqp2WJEV7 pic.twitter.com/4F6QoLgL34
— This Week (@ThisWeekABC) September 26, 2021
What he's saying: "I think we're going to submit this data pretty soon. It's a question of days, not weeks," Bourla said.
"Then it is up to the FDA to be able to review the data and come to their conclusions, and approve it or not."
"If they approve it, we will be ready with our manufacturing to provide this new formulation of the vaccine," Bourla said.
Like this article? Get more from Axios and subscribe to Axios Markets for free.